This tumor-specific population has a distinct epigenome, superior antitumor function, and can be enriched for adoptive cell therapy based on high IL-7R expression, without knowledge of tumor antigens, and may thus help improve melanoma therapy in the postsurgical or postimmunotherapy setting. This evidence concerns the gene IL7R and melanoma.